| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039974A2 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039973A2 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039971A2 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039704A1 A method for producing human kallikrein 1 |
| 04/02/2009 | WO2009039567A1 Molecular delivery vesicle |
| 04/02/2009 | WO2009021971A3 Novel targets and compounds for therapeutic intervention of hiv infection |
| 04/02/2009 | WO2009019458A3 Erythropoietin fusion proteins |
| 04/02/2009 | WO2009018333A3 Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells |
| 04/02/2009 | WO2009018179A3 Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease |
| 04/02/2009 | WO2009014382A3 Cxcl11 adjuvant compositions and uses thereof |
| 04/02/2009 | WO2009007714A3 Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour |
| 04/02/2009 | WO2009002203A8 Polyfunctional fullerene c60 aminoacid derivatives |
| 04/02/2009 | WO2008141282A3 Materials and methods for foxp3 tumor suppression |
| 04/02/2009 | WO2008113030A3 Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
| 04/02/2009 | WO2008110777A3 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 04/02/2009 | WO2008108649A3 Ace-inhibitory peptides from whey and methods for providing the same. |
| 04/02/2009 | WO2008094905A3 Encapsulated hdl mimetic peptides |
| 04/02/2009 | WO2008073627A3 Method of diagnosing and treating asthma |
| 04/02/2009 | WO2008069917A3 Novel cyclic peptides |
| 04/02/2009 | WO2008063213A3 Uses and compositions for treatment of psoriatic arthritis |
| 04/02/2009 | WO2008051448A3 Methods and compositions for efficient removal of protein a from binding molecule preparations |
| 04/02/2009 | WO2008051326A3 Identification of contactins and l1- cams as ligands for the amyloid precursor protein |
| 04/02/2009 | WO2008042826A3 Use of omentin 1 and omentin 2 in the diagnosis and treatment of disease |
| 04/02/2009 | WO2008005983A3 Pan-her antagonists and methods of use |
| 04/02/2009 | WO2007150046A3 Methods and compositions for treating ophthalmic conditions via modulation of megalin activity |
| 04/02/2009 | WO2007111952A3 Method of preparing glycopeptides |
| 04/02/2009 | WO2007100718A9 Neurotensin receptor agonists and opioid receptor agonists |
| 04/02/2009 | WO2006071451A3 Compounds that prevent macrophage apoptosis and uses thereof |
| 04/02/2009 | WO2006063133A3 Biomarker for inflammatory bowel disease |
| 04/02/2009 | WO2006028492A3 hC1Q/TNF7 AND USES THEREOF |
| 04/02/2009 | WO2006023530A3 Compositions and methods for enhancing structural and functional nervous system reorganization and recovery |
| 04/02/2009 | WO2005117930A3 Use of thioredoxin measurements for diagnostics and treatments |
| 04/02/2009 | WO2005097169A3 Novel immunotherapy |
| 04/02/2009 | WO2005072417A3 Vascular endothelial growth factors and methods of their use |
| 04/02/2009 | WO2005059094A3 Novel methods of inorganic compound discovery and synthesis |
| 04/02/2009 | WO2005033291A3 Hormone response element binding transregulators |
| 04/02/2009 | WO2004110358A3 Polymeric conjugates for tissue activated drug delivery |
| 04/02/2009 | WO2004110353A3 Novel immunomodulating peptide |
| 04/02/2009 | WO2004080394A3 Stat3 antagonists and their use as vaccines against cancer |
| 04/02/2009 | WO2004069199A3 Marketing system for improving patient compliance and methods and devices relating to same |
| 04/02/2009 | WO2003087125A3 A novel g protein-coupled purinergic receptor, gave 17 |
| 04/02/2009 | US20090088573 Biologically active peptides and compositions, their use |
| 04/02/2009 | US20090088558 Tumor necrosis factor specific antibody hybrid for use in treatment and prevention of autoimmune, rheumatoid arthritic, graft rejection and graft-versus-host disorder |
| 04/02/2009 | US20090088557 Novel semaphorin genes (i) |
| 04/02/2009 | US20090088555 44 Human Secreted Proteins |
| 04/02/2009 | US20090088458 N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators |
| 04/02/2009 | US20090088398 Recombinant adenoviral vectors and methods of use |
| 04/02/2009 | US20090088392 Treatment of melanoma |
| 04/02/2009 | US20090088391 Strains of Lactobacillus Helveticus which do not Ferment Lactose |
| 04/02/2009 | US20090088390 Polypeptide |